Medical/Pharmaceuticals
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia
HONG KONG, July 12, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial inAustralia. AK117 resulted in no dose...
2021-07-13 09:06
2416
Hochuen Medical Raises Tens of Millions RMB in Series A Financing
SHENZHEN, July 12, 2021 /PRNewswire/ -- Hochuen Medical Technology Co., Ltd. (hereinafter referred to as "Hochuen Medical") has raised a40 million Yuan (RMB) Series A round of financing led by Qiming Venture Partners as the sole investor. The new proceeds will be used to (1) accelerate the com...
2021-07-13 01:05
2271
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US
SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase...
2021-07-11 21:03
20360
HICOOL 2021 Global Entrepreneurship Competition (Preliminary Round) is Launched in Full Swing on July 10th
BEIJING, July 11, 2021 /PRNewswire/ -- On July 10th, HICOOL 2021 Global Entrepreneurship Competition (Qualifying Round) is launched in full swing. A total of 1,237 startups shortlisted for the preliminary round compete off-line inBeijing and online in a global context in six major industries: New...
2021-07-11 21:00
2303
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile * ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South Ko...
2021-07-09 21:00
3714
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...
2021-07-09 20:00
30516
Sequanta and Mission Bio announce strategic partnership
SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...
2021-07-09 15:44
2280
Nippon Express (India) Newly Acquires GDP Certification at Three Locations
TOKYO, July 8, 2021 /PRNewswire/ -- Nippon Express (India) Private Limited (hereinafter "NE India"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification in April for its temperature-controlled hubs inDelhi, Mumbai and Ahmedabad, evidencing the ...
2021-07-08 15:00
1558
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2623
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
18543
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
17675
Arctic Vision Joins Forces with the University of Hong Kong Department of Ophthalmology to Discover and Develop Novel Neuroprotective Therapies for Ocular Disease
SHANGHAI and HONG KONG, July 4, 2021 /PRNewswire/ -- Arctic Vision, a China -based clinical-stage ophthalmology company focuses on developing innovative therapies for pan-ocular diseases, announcing today a new research collaboration with Prof.Christopher Leung, Head and Clinical Professor at the ...
2021-07-05 08:00
1953
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
SUZHOU, China, July 2, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that promising anti-tumor response...
2021-07-02 21:02
3131
First Naturally-designed and Personalised Bioprosthesis SingValve Set to Revolutionise Heart Valve Surgery
SINGAPORE, July 1, 2021 /PRNewswire/ -- A naturally-designed human-like personalised heart valve bioprosthesis developed by a team of clinician-scientists from theNational University Health System (NUHS) looks set to be a game changer in the next generation of "personalised medicine" and further...
2021-07-01 21:00
3274
Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- Korea National Institute of
Health (KNIH), Korea's top research center in the field of hygiene and medicine
(with Mr. Kwon Jun-Wook as President) conducted a field inspection of key
companies with mRNA technology.
2021-07-01 21:00
2477
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
* First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors * China sites to join the dose expansion part of the study to accelerate TJ- CD4B/ABL111 development * Results of TJ-L14B/ABL503 preclinical studies accepted for publica...
2021-07-01 20:00
13634
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The patent secures a ...
2021-07-01 19:50
13940
Joint Commission International publishes fourth edition of International Accreditation Standards for Laboratories
Standards and policies in latest edition become effective 1 January 2022 OAK BROOK, Ill., July 1, 2021 /PRNewswire/ -- Joint Commission International (JCI) today publishedJoint Commission International Accreditation Standards for Laboratories, Fourth Edition. The manual provides requirements for ...
2021-07-01 08:00
1671
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points * GBM AGILE pivotal study of paxalisib is...
2021-06-30 22:00
30822
VUNO Inks Deal with Samsung Electronics to Embed AI-powered Algorithms in Samsung's Premium Mobile X-ray System
SEOUL, South Korea, June 30, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc., announced today a partnership with Samsung Electronics Co., Ltd., global medical device company to incorporate its AI-powered chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™, ...
2021-06-30 21:00
2039
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 310 media titles]
2026-04-16 17:15
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
iQIYI to Open Its First Central China Theme Park in Wuhan, Continuing to Bring IP Value Beyond the Screen
[Picked up by 292 media titles]
2026-04-10 11:38
Most Read
NYSE Content Update: Sourcery Founder Molly O'Shea Joins as a Media Partner
2026-04-10 21:14
7956
High Templar Tech Limited Files Its Annual Report on Form 20-F
2026-04-10 18:30
7870